VBI Vaccines Inc.
VBIV · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $8,682 | $1,082 | $631 | $1,061 |
| % Growth | 702.4% | 71.5% | -40.5% | – |
| Cost of Goods Sold | $14,497 | $11,276 | $10,770 | $9,168 |
| Gross Profit | -$5,815 | -$10,194 | -$10,139 | -$8,107 |
| % Margin | -67% | -942.1% | -1,606.8% | -764.1% |
| R&D Expenses | $9,343 | $15,506 | $19,558 | $14,859 |
| G&A Expenses | $42,143 | $56,120 | $38,335 | $20,651 |
| SG&A Expenses | $40,153 | $56,120 | $38,335 | $20,651 |
| Sales & Mktg Exp. | -$1,990 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $49,496 | $71,626 | $57,893 | $35,510 |
| Operating Income | -$55,311 | -$81,820 | -$68,032 | -$43,617 |
| % Margin | -637.1% | -7,561.9% | -10,781.6% | -4,110.9% |
| Other Income/Exp. Net | -$37,525 | -$31,483 | -$1,721 | -$2,613 |
| Pre-Tax Income | -$92,836 | -$113,303 | -$69,753 | -$46,230 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$92,836 | -$140,951 | -$72,650 | -$47,286 |
| % Margin | -1,069.3% | -13,026.9% | -11,513.5% | -4,456.7% |
| EPS | -5.96 | -16.37 | -8.55 | -6.5 |
| % Growth | 63.6% | -91.5% | -31.5% | – |
| EPS Diluted | -5.96 | -16.37 | -8.55 | -6.5 |
| Weighted Avg Shares Out | 15,572 | 8,609 | 8,498 | 7,276 |
| Weighted Avg Shares Out Dil | 15,572 | 8,609 | 8,498 | 7,276 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,663 | $1,387 | $372 | $613 |
| Interest Expense | $8,064 | $5,222 | $5,104 | $3,321 |
| Depreciation & Amortization | $1,990 | $2,061 | $1,835 | $1,652 |
| EBITDA | -$82,782 | -$106,020 | -$62,814 | -$41,257 |
| % Margin | -953.5% | -9,798.5% | -9,954.7% | -3,888.5% |